Tenaya Therapeutics (TNYA) Research & Development (2020 - 2026)

Tenaya Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• On a quarterly basis, Research & Development fell 29.57% year-over-year to $14.8 million in Q1 2026; TTM through Mar 2026 was $62.4 million, a 24.64% decrease from a year earlier, with the FY2025 full-year figure at $68.6 million, down 20.91% from the prior year.
• Research & Development held at $14.8 million in Q1 2026 per TNYA's latest filing, from $14.8 million in the prior quarter.
• Across five years, Research & Development topped out at $26.5 million in Q2 2023 and bottomed at $14.8 million in Q4 2025.
• The 5-year median for Research & Development is $22.6 million (2024), against an average of $21.3 million.
• Across the five-year window, Research & Development surged 151.88% in 2022 and declined 29.57% in 2026, its largest moves.
• Year by year, Research & Development stood at $25.7 million in 2022, then decreased by 11.2% to $22.9 million in 2023, then decreased by 18.27% to $18.7 million in 2024, then retreated by 20.82% to $14.8 million in 2025, then rose by 0.3% to $14.8 million in 2026.
• Per Business Quant, the three latest TNYA Research & Development figures stand at $14.8 million (Q1 2026), $14.8 million (Q4 2025), and $15.4 million (Q3 2025).